Dr. Matthew Barcus is a Senior Research Analyst at Chardan covering SMID cap biotech companies within the rare disease, oncology, infectious disease, and autoimmune space.

Dr. Matthew Barcus joined Chardan in the summer of 2021 from Wedbush Securities where he worked as an associate on the biotech equity research team. Prior to starting his career in finance, Dr. Barcus was a Postdoctoral Research Fellow at The University of Tokyo, where he studied the structural biology of endoglycosidases. Dr. Barcus conducted his thesis research at Cornell University, where his research focused on the structural and enzymatic characterization of lipolytic enzymes.

Dr. Barcus received his BS from Arizona State University, his PhD from Cornell University, and was a JSPS Postdoctoral Research Fellow at The University of Tokyo.